Research Topics
Genomes and Genes | K M GiacominiSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Pharmacogenomics and patient care: one size does not fit allKathleen M Giacomini
Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA 94143, USA
Sci Transl Med 4:153ps18. 2012..Here, we describe the status of the field and approaches for addressing some of the open questions in pharmacogenomics research and use of genetic testing in guiding drug therapy...
Role of organic cation transporter 1, OCT1 in the pharmacokinetics and toxicity of cis-diammine(pyridine)chloroplatinum(II) and oxaliplatin in miceShuanglian Li
Department of Bioengineering and Therapeutic Sciences, University of California, 1550 4th Street, San Francisco, California 94158, USA
Pharm Res 28:610-25. 2011....- The pharmacogenetics research network: from SNP discovery to clinical drug responseK M Giacomini
Department of Biopharmaceutical Sciences, University of California San Francisco, San Francisco, California, USA
Clin Pharmacol Ther 81:328-45. 2007..Seven major topics are included: informatics (PharmGKB), cardiovascular, pulmonary, addiction, cancer, transport, and metabolism... - Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMPCheryl D Cropp
Department of Biopharmaceutical Sciences, 1550 4th Street, RH584, Box 2911, University of California, San Francisco, CA 94158 2911, USA
Mol Pharmacol 73:1151-8. 2008..We conclude that hOAT2 is a highly efficient, facilitative transporter of cGMP and may be involved in cGMP signaling in many tissues. Our study suggests that hOAT2 represents a potential new drug target for regulating cGMP levels... - Molecular cloning and functional expression of a rabbit renal organic cation transporterS Terashita
Department of Biopharmaceutical Sciences, University of California, San Francisco 94143, USA
Biochim Biophys Acta 1369:1-6. 1998..rbOCT1 mRNA transcripts are expressed in the kidney, liver, and intestine... - Molecular cloning of a Na+-dependent nucleoside transporter from rabbit intestineK M Gerstin
Department of Biopharmaceutical Sciences, University of California, San Francisco 94143 0446, USA
Pharm Res 17:906-10. 2000..The goal of the present study was to clone the nucleoside transporters present in rabbit, an important preclinical animal model, and to functionally characterize the clone(s)... - Cloning and functional characterization of a rat renal organic cation transporter isoform (rOCT1A)L Zhang
Department of Biopharmaceutical Sciences, University of California, San Francisco, California 94143, USA
J Biol Chem 272:16548-54. 1997..These studies demonstrate the presence of a functional, alternatively spliced organic cation transporter (rOCT1A) in rat kidney... - Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentinT J Urban
Department of Biopharmaceutical Sciences, University of California San Francisco, San Francisco, California, USA
Clin Pharmacol Ther 83:416-21. 2008..These results provide clinical evidence of the role of genetic variation in renal drug transporters in active drug secretion in vivo... - Na(+)-dependent purine nucleoside transporter from human kidney: cloning and functional characterizationJ Wang
Department of Biopharmaceutical Sciences, University of California, San Francisco 94143, USA
Am J Physiol 273:F1058-65. 1997..In contrast, rat SPNT transcripts are absent in kidney and highly localized to liver and intestine. The hSPNT1 gene was localized to chromosome 15. This is the first demonstration of a purine nucleoside transporter in human kidney... 
The UCSF-FDA TransPortal: a public drug transporter databaseK M Morrissey
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, USA
Clin Pharmacol Ther 92:545-6. 2012..In this article, we inform the scientific community about the UCSF-FDA TransPortal, a new and valuable online resource for research and drug development...- Genetic variation in drug transporters in ethnic populationsC D Cropp
Department of Biopharmaceutical Sciences, University of California, San Francisco, San Francisco, California, USA
Clin Pharmacol Ther 84:412-6. 2008 - The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metforminS L Stocker
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA
Clin Pharmacol Ther 93:186-94. 2013..These findings suggest that promoter variants of MATE1 and MATE2 are important determinants of metformin disposition and response in healthy volunteers and diabetic patients... - Discovery of regulatory elements in human ATP-binding cassette transporters through expression quantitative trait mappingP Matsson
Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA
Pharmacogenomics J 12:214-26. 2012..Several of the associations were experimentally validated in reporter assays. Through influencing ABC expression levels, these single-nucleotide polymorphisms may affect disease susceptibility and response to drugs... - Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokineticsY Shu
Department of Biopharmaceutical Sciences, University of California San Francisco, San Francisco, California, USA
Clin Pharmacol Ther 83:273-80. 2008..Our studies suggest that OCT1 genotype is a determinant of metformin pharmacokinetics... - Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3)I Badagnani
Department of Biopharmaceutical Sciences, University of California, San Francisco, CA 94143 0446, USA
Pharmacogenomics J 5:157-65. 2005..The genetic analysis and functional characterization of CNT3 variants suggest that this transporter does not tolerate nonsynonymous changes and is important for human fitness... - Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transportersM J Dresser
Department of Biopharmaceutical Sciences, University of California San Francisco, 513 Parnassus Avenue, S-926, San Francisco, CA 94143-0446, USA
J Pharm Sci 90:397-421. 2001..With the development of new assays, reagents, and experimental methods, we will soon have a better understanding of the roles of each transporter isoform in the renal elimination of drugs... - Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) geneDeanna L Kroetz
Department of Biopharmaceutical Sciences, University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143 0446, USA
Pharmacogenetics 13:481-94. 2003.... - Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2Ryan P Owen
Department of Biopharmaceutical Sciences, University of California, San Francisco, San Francisco, California, USA
Pharmacogenet Genomics 15:83-90. 2005..However, CNT2-F355S (3% allele frequency in the African-American sample) was found to alter specificity for naturally occurring nucleosides, which may have implications for nucleoside homeostasis... - Functional characterization and haplotype analysis of polymorphisms in the human equilibrative nucleoside transporter, ENT2Ryan P Owen
Department of Biopharmaceutical Sciences, University of California, San Francisco, California 94158, USA
Drug Metab Dispos 34:12-5. 2006..The low overall genetic diversity in SLC29A2 makes it unlikely that variation in the coding region contributes significantly to clinically observed differences in drug response... - Genetic variation in human P450 oxidoreductaseWalter L Miller
Department of Pediatrics, University of California, San Francisco, United States
Mol Cell Endocrinol 300:180-4. 2009..A503V reduces both activities of P450c17 in half, but had no effect on CYP1A2 or 2C19. POR variants are a previously unappreciated source of genetic variation in patterns of steroid synthesis and drug metabolism... - The concentrative nucleoside transporter family, SLC28Jennifer H Gray
Department of Biopharmaceutical Sciences, University of California San Francisco, 513 Parnassus Ave, S 926, San Francisco, CA 94143 0446, USA
Pflugers Arch 447:728-34. 2004..Further, this family is involved in the absorption and disposition of many nucleoside analogs. Several CNT single nucleoside polymorphisms (SNPs) have been identified, but have yet to be characterized... - Localization of human equilibrative nucleoside transporters, hENT1 and hENT2, in renal epithelial cellsLara M Mangravite
Department of Biopharmaceutical Sciences, University of California, San Francisco, San Francisco, California 94143 0446, USA
Am J Physiol Renal Physiol 284:F902-10. 2003..These data suggest that hENT1 and hENT2 on the basolateral membrane function with concentrative nucleoside transporters on the apical membrane to mediate active reabsorption of nucleosides within the kidney... - Functional characterization of liver enhancers that regulate drug-associated transportersM J Kim
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA
Clin Pharmacol Ther 89:571-8. 2011..This work provides a general model for the rapid characterization of liver enhancers and identifies associations between enhancer variants and drug response... - A novel proton-dependent nucleoside transporter, CeCNT3, from Caenorhabditis elegansG Xiao
Department of Biopharmaceutical Sciences, School of Pharmacy, University of California, San Francisco, San Francisco, California, USA
Mol Pharmacol 59:339-48. 2001..The broad nucleoside specificity of CeCNT3 may be explained by this and other residues that restrict purine and pyrimidine nucleoside uptake and that discriminate among pyrimidine nucleosides... - Cloning and functional expression of a human liver organic cation transporterL Zhang
Department of Biopharmaceutical Sciences, University of California San Francisco 94143, USA
Mol Pharmacol 51:913-21. 1997..The functional expression of hOCT1 will provide a powerful tool for elucidation of the mechanisms of organic cation transport in the human liver and understanding of the mechanisms involved in the disposition and hepatotoxicity of drugs... - Molecular determinants of specificity for synthetic nucleoside analogs in the concentrative nucleoside transporter, CNT2Ryan P Owen
Department of Biopharmaceutical Sciences, The University of California, San Francisco, San Francisco, California 94158, USA
J Biol Chem 281:26675-82. 2006..Our data are consistent with a model in which an increased capability for hydrogen bonding in critical amino acids that reside in the C terminus of rCNT2 contributes to its enhanced selectivity for 2CdA... - Role of aromatic transmembrane residues of the organic anion transporter, rOAT3, in substrate recognitionBo Feng
Department of Biopharmaceutical Sciences, School of Pharmacy, University of California San Francisco, San Francisco, CA 94143 0446, USA
Biochemistry 41:8941-7. 2002..Aromatic residues in this pocket may interact directly with substrates of rOAT3 through hydrogen bonds and pi-pi interactions... - Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered functionMaya K Leabman
Department of Biopharmaceutical Sciences, Program in Human Genetics, University of California, San Francisco, CA 94143 0443, USA
Pharmacogenetics 12:395-405. 2002..This selection may be due to a necessary role of OCT2 in the renal elimination of endogenous amines or xenobiotics, including environmental toxins, neurotoxic amines and therapeutic drugs... - Genetic variants of human organic anion transporter 4 demonstrate altered transport of endogenous substratesJames E Shima
Dept of Bioengineering and Therapeutics Sciences, University of California, San Francisco, California 94143 2911, USA
Am J Physiol Renal Physiol 299:F767-75. 2010.... - Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidneyLara M Mangravite
Department of Biopharmaceutical Sciences, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143 0446, USA
Eur J Pharmacol 479:269-81. 2003..This review examines the role that these transporters play in renal disposition of nucleosides and nucleoside analogs in both systemic and kidney-specific therapies... - Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3L Chen
Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, CA 94158, USA
Pharmacogenomics J 13:110-20. 2013..Aberrant methylation contributes to the reduced expression of OCT3 in prostate cancer... - The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacologyD L Kroetz
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA
Clin Pharmacol Ther 87:109-16. 2010..At the crossroads of pharmacogenomics and transporter biology is the National Institutes of Health-funded Pharmacogenomics of Membrane Transporters (PMT) project, centered at the University of California, San Francisco... - Arginine 454 and lysine 370 are essential for the anion specificity of the organic anion transporter, rOAT3B Feng
Department of Biopharmaceutical Sciences and Department of Pharmaceutical Chemistry, School of Pharmacy, University of California, San Francisco 94143, USA
Biochemistry 40:5511-20. 2001..The studies provide the first insights into the molecular determinants that are critical for recognition and translocation of organic anions by a member of the organic anion transporter family... - Localization of GFP-tagged concentrative nucleoside transporters in a renal polarized epithelial cell lineL M Mangravite
Department of Biopharmaceutical Sciences, Cardiovascular Research Institute, University of California-San Francisco, San Francisco, CA 94143-0446, USA
Am J Physiol Renal Physiol 280:F879-85. 2001..Apical localization of these transporters suggests a role in renal nucleoside reabsorption and regulation of tubular function via the adenosine pathway... - Functional characteristics and steroid hormone-mediated regulation of an organic cation transporter in Madin-Darby canine kidney cellsY Shu
Department of Biopharmaceutical Sciences, University of California San Francisco, San Francisco, California 94143 0446, USA
J Pharmacol Exp Ther 299:392-8. 2001..Furthermore, our data demonstrate that steroid hormones induce the transcription of OCT2 in the kidney... - Screening a large reference sample to identify very low frequency sequence variants: comparisons between two genesC E Glatt
Neurogenetics Laboratory, Program in Human Genetics, University of California San Francisco, San Francisco, California, USA
Nat Genet 27:435-8. 2001..Both genes have unique roles in neuronal transmission, and variants in either gene might be associated with neurobehavioral phenotypes... - Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport functionYing Chen
Division of Clinical Pharmacology and Experimental Therapeutics, Department of Biopharmaceutical Sciences, University of California at San Francisco, San Francisco, CA 94158, USA
Pharmacogenomics J 9:127-36. 2009..These data suggest that nonsynonymous variants in hMATE1 may alter drug disposition and ultimately affect clinical drug response... - Functional genetic variation in the basal promoter of the organic cation/carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5)Harunobu Tahara
Department of Biopharmaceutical Sciences, University of California, San Francisco, San Francisco, CA 94158 2911, USA
J Pharmacol Exp Ther 329:262-71. 2009..However, there were significant effects of gender on carnitine plasma levels (p < 0.01). Further in vivo studies of OCTN2 promoter variants on carnitine disposition and variation in drug response are warranted... - Transport of thyroid hormones is selectively inhibited by 3-iodothyronamineAlexandra G Ianculescu
Department of Biochemistry and Biophysics, University of California at San Francisco, San Francisco, California, USA
Mol Biosyst 6:1403-10. 2010..Given that OATP1A2, OATP1C1, and MCT8 are all present in the brain, T(1)AM may play an important role in modulating thyroid hormone delivery and activity in specific target regions in the central nervous system... - Novel variants in human Aquaporin-4 reduce cellular water permeabilityMARCO D SORANI
Program in Biological and Medical Informatics, University of California, San Francisco, San Francisco, CA 94110, USA
Hum Mol Genet 17:2379-89. 2008..Our experiments provide insight into the function of the AQP4 protein. These nsSNPs may have clinical implications for patients with cerebral edema and related disorders... - Organic cation transporters are determinants of oxaliplatin cytotoxicityShuzhong Zhang
Department of Biopharmaceutical Sciences, Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA 94158, USA
Cancer Res 66:8847-57. 2006..The development of new anticancer drugs, specifically targeted to OCTs, represents a novel strategy for targeted drug therapy. The results of the present structure-activity studies indicate specific tactics for realizing this goal... - Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populationsJennifer H Gray
Department of Biopharmaceutical Sciences, University of California San Francisco, San Francisco, CA 94143 0446, USA
Mol Pharmacol 65:512-9. 2004..3 +/- 1.5 microM for CNT1-Val189Ile, p<0.05). These data suggest that common genetic variants of CNT1 may contribute to variation in systemic and intracellular levels of anti-cancer nucleoside analogs... - Identification and characterization of 3-iodothyronamine intracellular transportAlexandra G Ianculescu
Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, California 94143, USA
Endocrinology 150:1991-9. 2009..This type of transporter small interfering RNA screening approach can be used in general to identify the constellation of transporters that participate in the intracellular disposition of compounds... - Specificity of human and rat orthologs of the concentrative nucleoside transporter, SPNTKarin M Gerstin
Department of Biopharmaceutical Sciences, University of California, San Francisco, California 94143, USA
Am J Physiol Renal Physiol 283:F344-9. 2002..These data suggest that there are notable species differences in the specificity of SPNT for synthetic nucleoside analogs... - Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1Yan Shu
Department of Biopharmaceutical Sciences, Division of Clinical Pharmacology and Experimental Therapeutics, University of California, San Francisco, CA 94143 0446, USA
Proc Natl Acad Sci U S A 100:5902-7. 2003.... - Functional genomics of membrane transporters in human populationsThomas J Urban
Department of Biopharmaceutical Sciences, San Francisco, CA 94143, USA
Genome Res 16:223-30. 2006..These variants and the reduced function variants provide plausible candidates for disease susceptibility or variation in clinical drug response... - Identification and characterization of proximal promoter polymorphisms in the human concentrative nucleoside transporter 2 (SLC28A2)Sook Wah Yee
Department of Biopharmaceutical Sciences, University of California, 1550 4th Street, RH584, Box 2911, San Francisco, CA 94158 2911, USA
J Pharmacol Exp Ther 328:699-707. 2009..This SNP may play a role in variation in the pharmacokinetics and pharmacological effects of nucleoside analogs... - Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1Douglas H Osato
Department of Biopharmaceutical Sciences, University of California San Francisco, San Francisco, California 94143-0446, USA
Pharmacogenetics 13:297-301. 2003..These results, together with the observation that there are few haplotypes of ENT1, indicate that coding region variants of ENT1 do not contribute to inter-individual differences in response to nucleoside analog drugs... - Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variantsIlaria Badagnani
Department of Biopharmaceutical Sciences, University of California, 1550 4th Street, Box 2911, San Francisco, CA 94158, USA
J Pharmacol Exp Ther 318:521-9. 2006..Furthermore, genetic variation in OATP1A2 may contribute to variation in MTX disposition and response... - The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic geneNada Abla
Department of Biopharmaceutical Sciences, University of California, San Francisco, California, USA
J Pharmacol Exp Ther 325:859-68. 2008..Further studies are required to assess the clinical significance of this altered function and expression and to evaluate substrate specificity of this functional change... - The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomicsAndrew R Erdman
Department of Biopharmaceutical Sciences, University of California, San Francisco 94143 0446, USA
Am J Physiol Renal Physiol 290:F905-12. 2006..This variant exhibited a reduced ability to transport ES, but a preserved ability to transport CIM. These data suggest that genetic variation in OAT3 may contribute to variation in the disposition of drugs... - Sorting of rat SPNT in renal epithelium is independent of N-glycosylationLara M Mangravite
Department of Biopharmaceutical Sciences, University of California, San Francisco, San Francisco, California 94143-0446, USA
Pharm Res 20:319-23. 2003..Removal of sites N606 and N625 resulted in proteins of reduced molecular mass. None of the unglycosylated mutants localized differently than wild-type SPNT. CONCLUSION: N-linked glycosylation is not essential for polarized sorting... - Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metforminYing Chen
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California 94158, USA
Pharmacogenet Genomics 19:497-504. 2009..The goal of this study was to determine the effect of a genetic variant in the organic cation transporter 2 (OCT2), OCT2-808G/T, which results in an amino acid change, A270S, on the pharmacokinetics of the antidiabetic drug, metformin... - Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variationStephanie E Hesselson
Cardiovascular Research Institute, University of California San Francisco, San Francisco, California, United States of America
PLoS ONE 4:e6942. 2009..Collectively, these results suggest that the proximal promoter region of membrane transporters is rich in variation and that variants in these regions may play a role in interindividual variation in drug disposition and response... - Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteinsTsuyoshi Minematsu
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, 1550 4th Street, San Francisco, CA 94158, USA
Mol Cancer Ther 10:531-9. 2011..The study provides the basis for further clinical DDI studies with TKIs... - Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogueSwati S More
Department of Bioengineering and Therapeutic Sciences, University of California, 1550 4th Street, San Francisco, CA 94158, USA
Mol Cancer Ther 9:1058-69. 2010..Mol Cancer Ther; 9(4); 1058-69. (c)2010 AACR... - Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variantsTomoe Fujita
Department of Biopharmaceutical Sciences, University of California San Francisco, USA
J Pharm Sci 95:25-36. 2006..A variety of structurally diverse compounds have been shown to interact with OCT2, including endogenous compounds, drugs, and dietary supplements... - Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered functionLigong Chen
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158, USA
J Pharmacol Exp Ther 335:42-50. 2010..This study suggests that nonsynonymous variants of OCT1 in Chinese and Japanese populations may affect the differential response to metformin... - Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutationsNingwu Huang
Departments of Pediatrics and Biopharmaceutical Sciences, University of California, San Francisco, CA 94143, USA
Proc Natl Acad Sci U S A 105:1733-8. 2008..The activity of A503V was reduced to a modest but statistically significant degree in all four assays, suggesting that it may play an important role in interindividual variation in drug response... - Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2)Mark J Dresser
Department of Biopharmaceutical Sciences, University of California, San Francisco, 94143-0446, USA
Pharm Res 19:1244-7. 2002 - Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4)Thomas J Urban
Departments of aBiopharmaceutical Sciences, University of California San Francisco, San Francisco, California, USA
Pharmacogenet Genomics 17:773-82. 2007..Genetic variation in OCTN1 may help to explain interindividual variability in the pharmacokinetics of many cationic or zwitterionic drugs... - Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion familyYing Chen
Department of Biopharmaceutical Sciences, University of California, San Francisco, 1550 4th St, San Francisco, CA 94158, USA
J Pharmacol Exp Ther 322:695-700. 2007..These transporters may play an important role in the accumulation and renal excretion of PQ, and they may serve as molecular targets for the prevention and treatment of PQ-induced nephrotoxicity... - Estimating the contribution of genes and environment to variation in renal drug clearanceMaya K Leabman
Department of Biopharmaceutical Sciences, University of California, San Francisco, San Francisco, CA 94143-0446, USA
Pharmacogenetics 13:581-4. 2003..g. glomerular filtration and passive secretion/reabsorption). The low rGC values of iohexol, digoxin and terodiline suggest that environmental factors may contribute to variation in their renal clearance... - Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1)Tomoe Fujita
Department of Pharmacology, Kitasato University School of Medicine, Sagamihara, Kanagawa, 228 8555, Japan
Pharmacogenet Genomics 15:201-9. 2005..The goal of this study was to identify and functionally characterize OAT1 variants as a first step towards understanding whether genetic variation in OAT1 may contribute to interindividual differences in renal elimination of xenobiotics... - Haplotype structure and ethnic-specific allele frequencies at the OCTN locus: implications for the genetics of Crohn's diseaseThomas J Urban
Inflamm Bowel Dis 11:78-9. 2005 - PharmGKB submission update: VI. PMT submissions of genetic variations in neurotransmitter transporters (SLC6, SLC17, and SLC18) to the PharmGKB networkIlaria Badagnani
Department of Biopharmaceutical Sciences, University of California, San Francisco, USA
Pharmacol Rev 58:5-6. 2006 - Identifying genetic risk factors for serious adverse drug reactions: current progress and challengesRussell A Wilke
Department of Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, Wisconsin 53226, USA
Nat Rev Drug Discov 6:904-16. 2007..Key challenges for the discovery of predictive risk alleles for these SADRs are also considered... - PharmGKB submission update: V. PMT submissions of genetic variation in SLC22 family transportersYan Shu
Department of Biopharmaceutical Sciences, University of California, San Francisco, USA
Pharmacol Rev 58:3-4. 2006 - Natural variation in human membrane transporter genes reveals evolutionary and functional constraintsMaya K Leabman
Department of Biopharmaceutical Sciences, University of California, San Francisco, CA 94143-0446, USA
Proc Natl Acad Sci U S A 100:5896-901. 2003..In addition, African Americans exhibited a much higher frequency of population specific medium-frequency alleles than did European Americans... - PharmGKB submission update: IV. PMT submissions of genetic variations in ATP-Binding cassette transporters to the PharmGKB networkTan D Nguyen
Department of Biopharmaceutical Sciences, University of California, San Francisco, USA
Pharmacol Rev 58:1-2. 2006 - cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospectsKatherine S Lovejoy
Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
Proc Natl Acad Sci U S A 105:8902-7. 2008..These exceptional characteristics indicate that cDPCP and related complexes merit consideration as therapeutic options for treating colorectal and other cancers bearing appropriate cation transporters... - Creating and evaluating genetic tests predictive of drug responseScott T Weiss
Channing Laboratory, Brigham and Women s Hospital, 181 Longwood Ave, Boston, Massachusetts 02115, USA
Nat Rev Drug Discov 7:568-74. 2008.... - PharmGKB update: I. Genetic variants of the organic cation transporter 2 (OCT2, SLC22A2)Maya K Leabman
Pharmacogenetics of Membrane Transporters Group, Department of Biopharmaceutical Sciences, University of California San Francisco, USA
Pharmacol Rev 55:399. 2003 - Pharmacogenomics: challenges and opportunitiesDan M Roden
Vanderbilt University, Nashville, Tennessee, USA
Ann Intern Med 145:749-57. 2006..Overcoming these challenges holds the promise of improving new drug development and ultimately individualizing the selection of appropriate drugs and dosages for individual patients...